VivoSim Labs, Inc. (NASDAQ:VIVS) Sees Large Drop in Short Interest

VivoSim Labs, Inc. (NASDAQ:VIVS) saw a large decline in short interest in July. As of July 15th, there was short interest totaling 48,730 shares, a decline of 57.2% from the June 30th total of 113,911 shares. Based on an average daily trading volume, of 11,401,344 shares, the days-to-cover ratio is currently 0.0 days. Currently, 1.4% of the shares of the stock are sold short.

Analyst Ratings Changes

Separately, Weiss Ratings lowered VivoSim Labs from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 22nd. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company has a consensus rating of “Sell”.

Institutional Trading of VivoSim Labs

An institutional investor recently bought a new stake in VivoSim Labs stock. Two Sigma Investments LP purchased a new position in VivoSim Labs, Inc. (NASDAQ:VIVS) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 23,192 shares of the company’s stock, valued at approximately $68,000. Two Sigma Investments LP owned approximately 0.89% of VivoSim Labs as of its most recent SEC filing. 8.23% of the stock is owned by institutional investors and hedge funds.

VivoSim Labs Stock Down 8.9%

NASDAQ VIVS traded down $0.03 during trading hours on Wednesday, reaching $0.35. The company’s stock had a trading volume of 658,801 shares, compared to its average volume of 2,203,570. VivoSim Labs has a 1 year low of $0.33 and a 1 year high of $5.30. The company has a market capitalization of $1.21 million, a price-to-earnings ratio of -0.06 and a beta of 1.40. The firm’s 50-day moving average price is $1.00 and its 200-day moving average price is $1.51.

VivoSim Labs (NASDAQ:VIVS) last announced its quarterly earnings data on Tuesday, July 14th. The company reported ($2.21) earnings per share (EPS) for the quarter. The company had revenue of $0.04 million for the quarter. VivoSim Labs had a negative net margin of 10,567.17% and a negative return on equity of 277.62%.

VivoSim Labs Company Profile

VivoSim Labs, Inc (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.

The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology.